Clinical trials: Metastatic Colorectal Carcinoma
Colorectal Cancer
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
This is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type…
- Trial name
- NCT07595276
- Testing
- Enlituo®, Erbitux®
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Colorectal Adenocarcinoma
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
The purpose of this study is to collect information about the antitumor activity and the safety of capecitabine and thalidomide in patients with colorectal cancer.
- Trial name
- NCT00165217
- Testing
- Capecitabine, Thalidomide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer Metastatic
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
This is a phase I, open-label clinical study of BioTTT001 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.
- Trial name
- NCT06283134
- Testing
- BioTTT001 hepatic artery infusion, toripalimab, regorafenib
- Volunteers
- 60 people
- Sponsor
- China Medical University, China
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Colorectal Cancer
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
This study is evaluating the combination of Y-90 radioembolization followed by SBRT with the immunotherapy drugs, durvalumab and tremelimumab, to improve disease control of liver metastases for patients with microsatellite stable…
- Trial name
- NCT03802747
- Testing
- Durvalumab, Durvalumab and Tremelimumab, Y-90 Selective Internal Radiation Therapy (SIRT)
- Sponsor
- University of Colorado, Denver
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
This observational study will assess the progression-free survival, overall response and safety of Avastin (bevacizumab) in combination with chemotherapy in a real life setting in patients with metastatic colorectal cancer.
- Trial name
- NCT01266564
- Where
- 14 sites in Lebanon
- Volunteers
- 205 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer
This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectosigmoid Adenocarcinoma, Recurrent Rectal Adenocarcinoma
- Trial name
- NCT02874885
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer Metastatic
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Primary Objective: To assess efficacy aflibercept + 5-fluorouracil (5-FU)/levofolinate/irinotecan (FOLFIRI) by objective response rate (ORR).
- Trial name
- NCT01882868
- Testing
- Aflibercept, Levofolinate, Irinotecan
- Where
- 19 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and change in disease activity of intravenously (IV) infused telisotuzumab…
- Trial name
- NCT06614192
- Testing
- Telisotuzumab Adizutecan
- Where
- 51 sites in United States, Australia and 5 more
- Volunteers
- 74 people
- Sponsor
- AbbVie
Refractory Metastatic Colorectal Cancer, pMMR
QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
This is a single-arm,open-label, prospective, single-center Study of QL1101 and JS001 in patients with pMMR/MSS refractory metastatic colorectal cancer.
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- BEVTOR (NCT04527068)
- Testing
- Bevacizumab, Tripleitriumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Microsatellite-stable Colorectal Cancer
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable…
- Trial name
- NCT04068610
- Testing
- Durvalumab, Oleclumab, FOLFOX
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 61 people
- Sponsor
- MedImmune LLC
Colorectal Cancer, Peritoneal Metastases
Development and Validation of a PSN-AI Prediction Model
Heterogeneity concerning survival in synchronous peritoneal metastasis from patients with colorectal cancer exists, thereby further classification is urgently required.
- Trial name
- PSN-AI (NCT06231524)
- Testing
- Analyse pathologic slides
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer
Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study
Colorectal cancer (CRC) is the fourth leading cause of cancer death worldwide, claiming approximately 900,000 lives annually. In China, CRC has become one of the top three most common cancers, with about 555,000 new cases and…
- Trial name
- NCT07491159
- Testing
- Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil, Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Colo-rectal Cancer
LOTCOL Study: Local Treatment of Colo-rectal Liver Met
In this study the investigators will include colo-rectal cancer (CRC) patients starting last line of standard palliative chemotherapy.
- Trial name
- LOTCOL (NCT01867918)
- Testing
- Radiofrequency ablation, microwave, radiation therapy, Standard Chemotherapy
- Where
- Norway
- Volunteers
- 3 people
- Sponsor
- Oslo University Hospital
Metastatic Solid Cancers, Colorectal Cancer
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses.
- Conditions
- Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT06253520
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
The aim of this study is to assess the efficacy of 166Ho-TARE followed by maintenance therapy with fluoropyrimidine and anti-EGFR or bevacizumab in liver-limited unresectable colorectal cancer patients, in terms of progression…
- Trial name
- HAITI (NCT06332079)
- Testing
- 166Holmium TARE, Cetuximab, Panitumumab
- Where
- Italy
- Volunteers
- 4 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Metastatic Colorectal Cancer
COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
Treatment of metastatic colorectal cancer needs chemotherapy in most of the cases. During these last years, many new chemotherapies and targeted therapies have been developed improving significantly the overall survival of…
- Trial name
- NCT01596790
- Testing
- Blood analysis by EPISPOT and Cellsearch
- Where
- France
- Volunteers
- 168 people
- Sponsor
- University Hospital, Montpellier
Cancer Colorectal, Metastasis
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.
Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study.
- Trial name
- TWICE-IRI (NCT04392479)
- Testing
- Aflibercept-FOLFIRI, Aflibercept-mFOLFIRI3
- Where
- France
- Volunteers
- 202 people
- Sponsor
- Hôpital Franco-Britannique-Fondation Cognacq-Jay
Colorectal Cancer
A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
This expanded access study will assess the efficacy and safety of intravenous (IV) bevacizumab in combination with chemotherapy regimens as first-line treatment of metastatic cancer of the colon or rectum.
- Trial name
- NCT02582970
- Testing
- 5-Fluorouracil, Bevacizumab, Irinotecan
- Where
- 8 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)